전두측두엽 치매 시장 - 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• The Frontotemporal Dementia market in the 7MM is expected to grow at a steady Compound Annual Growth Rate (CAGR) of 14.1% during the forecast period. Key market drivers include increasing disease awareness, improved diagnostic tools, and ongoing research advancements.
• In 2023, the Frontotemporal Dementia market size in the 7MM was approximately 112 million that is further expected to increase by 2034.
• The current Frontotemporal Dementia treatment strategies mainly rely upon the off-label use of medications for symptomatic management, and most Indication Therapies therapies lack quality evidence from randomized, placebo-controlled Frontotemporal Dementia clinical trials.
• Frontotemporal Dementia approximately accounted for 129 thousand cases in 2023 in the 7MM, the Frontotemporal Dementia treatment market lacks approved therapy specific to Frontotemporal Dementia treatment.
• Alector Inc. /GSK's Latozinemab (AL001) is being developed for treating patients with Frontotemporal Dementia due to a progranulin gene mutation (Frontotemporal Dementia-GRN). It is estimated to launch by 2025 in the US. This emerging therapy have the potential to create a significant positive shift in the Frontotemporal Dementia market.
• In February 2024, Alector, Inc. reported that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (Frontotemporal Dementia-GRN).

DelveInsight's "Frontotemporal Dementia Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Frontotemporal Dementia, historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Frontotemporal Dementia treatment market report provides current treatment practices, emerging Frontotemporal Dementia drugs, market share of individual Frontotemporal Dementia therapies, and current and forecasted 7MM Frontotemporal Dementia market size from 2020 to 2034. The report also covers current Frontotemporal Dementia treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Frontotemporal Dementia market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Frontotemporal Dementia Treatment Market

Frontotemporal Dementia Overview

Frontotemporal Dementia is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (Frontotemporal Dementia): behavioral variant frontotemporal dementia (bvFrontotemporal Dementia), primary progressive aphasia (PPA), and movement disorders.

Frontotemporal Dementia occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking.

Frontotemporal Dementia Diagnosis

Frontotemporal Dementia can be hard to diagnose as it displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years. Diagnosis of Frontotemporal Dementia currently includes Imaging and blood or cerebrospinal fluid studies. A 'definite' diagnosis of Frontotemporal Dementia is still based on neuropathology confirmation postmortem. Diagnostic markers currently used for Frontotemporal Dementia include imaging and blood or cerebrospinal fluid studies. They may best serve a diagnostic role when used in a multimodal approach to achieve a 'definite' diagnosis of Frontotemporal Dementia in the living patient as soon as possible.

Frontotemporal Dementia Treatment

The management of problematic behaviors in Frontotemporal Dementia with mainly sparse case reports and case series detailing their effectiveness lacks the study quality. The main purpose of nonpharmacological interventions-described below-is to prevent disruptive behaviors, provide symptom relief, and lessen caregiver distress.

Diet and lifestyle

Regular driving assessments should be conducted. Poor judgment, gaze abnormalities, executive dysfunction, and motor difficulties may all affect safe driving macologic treatment of cognitive symptoms

In Frontotemporal Dementia and related disorders, donepezil, rivastigmine, and galantamine are the three most commonly used acetylcholinesterase. Although none were adequately powered, and only one study was placebo-controlled, results have been disappointing across the board.

Continued in the report...

Frontotemporal Dementia Epidemiology

As the Frontotemporal Dementia market is derived using the patient-based model, the Frontotemporal Dementia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Diagnosed Prevalent Cases of Frontotemporal Dementia, Type-specific Diagnosed Prevalent Cases of Frontotemporal Dementia, and Gene-specific Diagnosed Prevalent Cases of Frontotemporal Dementia in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The United States contributed to the largest diagnosed prevalent population of Frontotemporal dementia, acquiring ~46% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 45% and 9% of the total population share, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest number of Frontotemporal dementia cases followed by France, whereas Spain accounted for the lowest number of cases in 2023.
• A higher number of diagnosed cases were estimated in the Behavioral variant Frontotemporal Dementia (bvFrontotemporal Dementia) with around 36 thousand cases in the US in 2023.
• According to DelveInsight estimates, when the diagnosed prevalent cases of Frontotemporal Dementia are segmented based on the genes, there were around 17 thousand cases of C9orf72, followed by MAPT Microtubule-associated protein tau with 16 thousand cases, GRN Progranulin around 14 thousand, and for others, approximately one thousand cases were estimated, in the 7MM in 2023.

Recent Developments in the Frontotemporal Dementia Market

• Oct 8, 2024 - AviadoBio Ltd. and Astellas Pharma Inc. have partnered under an exclusive option and license agreement for AVB-101, a gene therapy in Phase I/II development for frontotemporal dementia caused by progranulin mutations. This rare form of early-onset dementia leads to rapid cognitive decline and is often underrecognized in those under 65.
• On October 3, 2024, AC Immune, a Swiss biopharmaceutical company, announced that its partner, Life Molecular Imaging (LMI) of Germany, received Fast Track Designation from the U.S. FDA for its Tau PET tracer, [18F]PI-2620. This PET tracer is designed to bind to a specific form of tau protein associated with Alzheimer's disease and Frontotemporal Dementia. By making this form of tau visible through PET imaging, it enables researchers and medical professionals to track its distribution and measure associated metabolic changes.

Frontotemporal Dementia Drug Chapters

The drug chapter segment of the Frontotemporal Dementia report encloses a detailed analysis of marketed Frontotemporal Dementia drugs and late-stage (Phase-III and Phase-II) pipeline Frontotemporal Dementia drugs. It also helps to understand the Frontotemporal Dementia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Frontotemporal Dementia Drugs

Latozinemab (AL001): Alector Inc. /GSK

Latozinemab (AL001), developed by Alector in collaboration with GSK, is indeed an investigational human monoclonal antibody designed to modulate progranulin (PGRN), a critical regulator of immune activity in the brain. This investigational therapy targets Frontotemporal Dementia with a progranulin gene mutation (Frontotemporal Dementia-GRN) by inhibiting the SORT1 receptor, which degrades PGRN, thereby increasing its levels in the brain. Latozinemab is currently in Phase III Frontotemporal Dementia clinical trials under the INFRONT-3 study and has recently been granted Breakthrough Therapy Designation by the FDA. This designation is significant as it facilitates an expedited review process due to the high unmet need for Frontotemporal Dementia-GRN treatment.

PBFT02: Passage Bio

It is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the granulin (GRN) gene to a patient's cells. The therapy is administered via a single injection into the cerebrospinal fluid at the cisterna magna (ICM injection), with the goal of producing higher-than-normal levels of progranulin protein (PGRN) within the central nervous system (CNS). This approach is intended to counteract progranulin deficiency in individuals with GRN gene mutations, which are associated with certain neurodegenerative conditions. It is currently being evaluated in Phase I/II clinical trials for treating Frontotemporal Dementia and mutations in the progranulin gene.

Frontotemporal Dementia Market Outlook

Current treatment approaches emphasize nonpharmacological interventions, particularly in the early stages, with pharmacological treatments serving as adjunctive therapies. However, DelveInsight's analysis focuses exclusively on pharmacological treatments, categorizing the Frontotemporal Dementia drugs market by drug classes, including SSRIs, antipsychotics, cholinesterase inhibitors, NMDA receptor antagonists, and benzodiazepine antianxiety drugs. Although these interventions offer limited clinical benefits, recent advances in Frontotemporal Dementia research have led to the development of novel Frontotemporal Dementia therapies targeting genetic, molecular, and autoimmune factors.

Emerging Frontotemporal Dementia therapies in the Frontotemporal Dementia pipeline, such as Latozinemab, PBFT02, PR006, and others are advancing through Frontotemporal Dementia clinical trials, with Latozinemab, in Phase III, positioned as the frontrunner.

• According to DelveInsight analysis, the US accounted for the highest market size of USD 68 million, with significant market share of Frontotemporal Dementia in year 2023 in the 7MM. The Frontotemporal Dementia market size of the 7MM is anticipated to increase in the forecast period (2024-2034), due to the expected launch of emerging Frontotemporal Dementia therapies.
• Among EU4 and the UK, Germany accounted for the highest market size of Frontotemporal Dementia with approximately 26% of the total Frontotemporal Dementia market size of EU4 and the UK in the year 2023, while Spain accounted for the lowest market in the same year.
• As per DelveInsight estimates, the Frontotemporal Dementia market size in Japan was approximately USD 8 million in year 2023. These numbers are expected to increase during the forecasted period.

Frontotemporal Dementia Drugs Uptake

This section focuses on the rate of uptake of the potential Frontotemporal Dementia drugs expected to be launched in the market during the study period 2020-2034. For example, for Latozinemab (AL001), we expect the drug uptake to be Medium-fast with a probability-adjusted peak share of around 60%, and years to the peak is expected to be 5 years from the year of launch.

Frontotemporal Dementia Pipeline Development Activities

The Frontotemporal Dementia market report provides insights into different Frontotemporal Dementia clincial trials within Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for emerging Frontotemporal Dementia therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Frontotemporal Dementia evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, include VA Medical Center, Seattle, Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University, Department of Psychiatry at Technische Universitat Munchen and Others.

Delveinsight's analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns of Frontotemporal Dementia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement is a crucial factor affecting the drug's market access. Often, the decision to reimburse comes down to the drug's price relative to the benefit it produces in treated patients.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Frontotemporal Dementia Therapeutics Market Report

• The Frontotemporal Dementia therapeutics market report covers a segment of key events, an executive summary, descriptive overview of Frontotemporal Dementia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape
• A detailed review of the Frontotemporal Dementia market; historical and forecasted Frontotemporal Dementia market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach
• The Frontotemporal Dementia therapeutics market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Frontotemporal Dementia market

Frontotemporal Dementia Therapeutics Market Report Insights

• Frontotemporal Dementia Patient Population
• Frontotemporal Dementia Therapeutic Approaches
• Frontotemporal Dementia Pipeline Analysis
• Frontotemporal Dementia Market Size and Trends
• Existing and future Market Opportunity

Frontotemporal Dementia Therapeutics Market Report Key Strengths

• 11 years Forecast
• 7MM Coverage
• Frontotemporal Dementia Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Frontotemporal Dementia Drugs Uptake
• Key Frontotemporal Dementia Market Forecast Assumptions

Frontotemporal Dementia Therapeutics Market Report Assessment

• Current Frontotemporal Dementia Treatment Practices
• Frontotemporal Dementia Unmet Needs
• Frontotemporal Dementia Pipeline Product Profiles
• Frontotemporal Dementia Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Frontotemporal Dementia Market Drivers
• Frontotemporal Dementia Market Barriers

Key Questions:

Frontotemporal Dementia Market Insights:

• What was the total Frontotemporal Dementia market size, the Frontotemporal Dementia Market market size by therapies, and market share (%) distribution in 2020, and how it would all look in 2034? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Frontotemporal Dementia?
• How is Latozinemab (AL001) going to compete with other treatments?
• Which drug is going to be the largest contributor in 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Frontotemporal Dementia Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Frontotemporal Dementia? What will be the growth opportunities across the 7MM concerning the patient population of Frontotemporal Dementia?
• What is the historical and forecasted Frontotemporal Dementia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Which type is more prevalent and why?
• What factors are affecting the diagnosis of the indication?

Current Frontotemporal Dementia Treatment Scenario, Marketed Frontotemporal Dementia Drugs, and Emerging Therapies:

• What are the current options for the treatment of Frontotemporal Dementia? What are the current treatment guidelines for the treatment of Frontotemporal Dementia in the US and Europe?
• How many Frontotemporal Dementia companies are developing therapies for the treatment of Frontotemporal Dementia?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Frontotemporal Dementia?
• What are the recent novel therapies, targets, Frontotemporal Dementia mechanism of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Frontotemporal Dementia?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted market of Frontotemporal Dementia?

Reasons to buy Frontotemporal Dementia Therapeutics Market Report

• The Frontotemporal Dementia treatment market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Frontotemporal Dementia Market
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing Frontotemporal Dementia market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming Frontotemporal Dementia players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Conjoint analysis section to provide visibility around leading classes.
• Highlights of Market Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing Frontotemporal Dementia treatment market to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Frontotemporal Dementia treatment market so that the upcoming Frontotemporal Dementia companies can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Frontotemporal Dementia Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key Frontotemporal Dementia players in the Frontotemporal Dementia market?

The Frontotemporal Dementia market is quite robust. The major Frontotemporal Dementia players are Alector Inc. /GSK., Pssage Bio, Prevail Therapeutics, and others which are currently developing Frontotemporal Dementia drugs for the treatment of Frontotemporal Dementia.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Frontotemporal Dementia market?

The increase in diagnosed prevalent cases of Frontotemporal Dementia and the launch of emerging therapies are attributed to be the key drivers for the increasing Frontotemporal Dementia market.

5. What is the expected impact of emerging therapies or advancements in Frontotemporal Dementia treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Frontotemporal Dementia treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key Frontotemporal Dementia players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Frontotemporal Dementia market.

Table of Contents

1 Key Insights

2 Report Introduction

3 Frontotemporal Dementia (FTD) Market Overview at a Glance

• 3.1 Market Share (%) Distribution of FTD by Therapies in 2020
• 3.2 Market Share (%) Distribution of FTD by Therapies in 2034

4 Epidemiology and Market Methodology of FTD

5 Executive Summary of Frontotemporal Dementia

6 Key Events

7 Disease Background and Overview: Frontotemporal Dementia

• 7.1 Introduction
• 7.2 Clinical Manifestations
• 7.3 Causes
• 7.4 Pathophysiology
• 7.5 Genetics
• 7.6 Related FTD Syndromes
• 7.7 Diagnosis
  • 7.7.1 Diagnostic Guidelines
    • 7.7.1.1 The Association for Frontotemporal Dementia (AFTD)
    • 7.7.1.2 Social Care Institute for Excellence Guideline
    • 7.7.1.3 Guideline from the American College of Physicians and the American Academy of Family Physicians
  • 7.7.2 Diagnostic Algorithm
• 7.8 Treatment and Management
  • 7.8.1 Treatment Algorithm
  • 7.8.2 Treatment Recommendations
    • 7.8.2.1 Guidelines American College of Physicians and the American Academy of Family Physicians
    • 7.8.2.2 The Association for Frontotemporal Dementia (AFTD)

8 Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale: The 7MM
  • 8.2.1 Diagnosed Prevalent Cases of FTD
  • 8.2.2 Type-specific Diagnosed Prevalent Cases of FTD
  • 8.2.3 Gene-specific Diagnosed Prevalent Cases of FTD
• 8.3 Total Diagnosed Prevalent Cases of FTD in the 7MM
• 8.4 The United States
  • 8.4.1 Diagnosed Prevalent Cases of FTD in the United States
  • 8.4.2 Type-specific Diagnosed Prevalent Cases of FTD in the United States
  • 8.4.3 Gene-specific Diagnosed Prevalent Cases of FTD in the United States
• 8.5 EU4 and the UK
  • 8.5.1 Germany
    • 8.5.1.1 Diagnosed Prevalent Cases of FTD
    • 8.5.1.2 Type-specific Diagnosed Prevalent Cases of FTD
    • 8.5.1.3 Gene-specific Diagnosed Prevalent Cases of FTD
  • 8.5.2 France
    • 8.5.2.1 Diagnosed Prevalent Cases of FTD
    • 8.5.2.2 Type-specific Diagnosed Prevalent Cases of FTD
    • 8.5.2.3 Gene-specific Diagnosed Prevalent Cases of FTD
  • 8.5.3 Italy
    • 8.5.3.1 Diagnosed Prevalent Cases of FTD
    • 8.5.3.2 Type-specific Diagnosed Prevalent Cases of FTD
    • 8.5.3.3 Gene-specific Diagnosed Prevalent Cases of FTD
  • 8.5.4 Spain
    • 8.5.4.1 Diagnosed Prevalent Cases of FTD
    • 8.5.4.2 Type-specific Diagnosed Prevalent Cases of FTD
    • 8.5.4.3 Gene-specific Diagnosed Prevalent Cases of FTD
  • 8.5.5 The United Kingdom
    • 8.5.5.5 Diagnosed Prevalent Cases of FTD
    • 8.5.5.6 Type-specific Diagnosed Prevalent Cases of FTD
    • 8.5.5.7 Gene-specific Diagnosed Prevalent Cases of FTD
• 8.6 Japan
  • 8.6.1 Diagnosed Prevalent Cases of FTD in Japan
  • 8.6.2 Type-specific Diagnosed Prevalent Cases of FTD in Japan
  • 8.6.3 Gene-specific Diagnosed Prevalent Cases of FTD in Japan

9 Frontotemporal Dementia Patient Journey

10 Frontotemporal Dementia Emerging Therapies

• 10.1 Key Cross Competition
• 10.2 Latozinemab (AL001): Alector Inc. /GSK
  • 10.2.1 Product Description
  • 10.2.2 Other Developmental Activities
  • 10.2.3 Clinical Trials Information
  • 10.2.4 Safety and Efficacy
  • 10.2.5 Analyst Views
• 10.3 PBFT02: Passage Bio, Inc.
  • 10.3.1 Product Description
  • 10.3.2 Other Developmental Activities
  • 10.3.3 Clinical Trials Information
  • 10.3.4 Safety and Efficacy
  • 10.3.5 Analyst Views

11 Frontotemporal Dementia: Seven Major Market Analysis

• 11.1 Key Findings: Market
• 11.2 Key Market Forecast Assumption
• 11.3 Frontotemporal Dementia Market Outlook
• 11.4 Total Market Size of FTD in the 7MM
• 11.5 Market Size of FTD by Therapies in the 7MM
• 11.6 The United States Market Size
  • 11.6.1 Total Market Size of FTD in the United States
  • 11.6.2 Market Size of FTD by Therapies
• 11.7 Market Size of FTD in EU4 and the UK
  • 11.7.1 Germany
    • 11.7.1.1 Total Market Size of FTD in the Germany
    • 11.7.1.2 The Market Size of FTD by Therapies in Germany
  • 11.7.2 France
    • 11.7.2.1 Total Market Size of FTD in the France
    • 11.7.2.2 The Market Size of FTD by Therapies in France
  • 11.7.3 Spain
    • 11.7.3.1 Total Market Size of FTD in the Spain
    • 11.7.3.2 The Market Size of FTD by Therapies in Spain
  • 11.7.4 Italy
    • 11.7.4.1 Total Market Size of FTD in the Italy
    • 11.7.4.2 The Market Size of FTD by Therapies in Italy
  • 11.7.5 The UK
    • 11.7.5.1 Total Market Size of FTD in the UK
    • 11.7.5.2 The Market Size of FTD by Therapies in the UK
• 11.8 Japan Market Size
  • 11.8.1 Total Market Size of FTD in Japan
  • 11.8.2 Market Size of FTD by Therapies in Japan

12 KOL Views

13 SWOT Analysis

14 Frontotemporal Dementia Unmet Needs

15 Reimbursement and Market Access

• 15.1 United States
  • 15.1.1 Centers for Medicare & Medicaid Services (CMS)
• 15.2 In EU4 and the UK
  • 15.2.1 Germany
  • 15.2.2 France
  • 15.2.3 Italy
  • 15.2.4 Spain
  • 15.2.5 The United Kingdom
• 15.3 Japan
  • 15.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Abbreviations and Acronyms
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer